On 8 April 2015, the Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to conduct a supplementary assessment for Commission A14-44 (Ledipasvir / sofosbuvir – Benefit assessment according to §35a Social Code Book (SGB) V).
http://ift.tt/2ryB0q5
Παρασκευή 16 Ιουνίου 2017
Ledipasvir / Sofosbuvir (Addendum to Commission A14-44) [Internet].
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Summary Insulinomas are rare neuroendocrine tumours that classically present with fasting hypoglycaemia. This case report discusses an un...
-
The online platform for Taylor & Francis Online content New for Canadian Journal of Remote Sen...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου